vs
Side-by-side financial comparison of BIOMERICA INC (BMRA) and Anbio Biotechnology (NNNN). Click either name above to swap in a different company.
Biomerica Inc. is a global medical technology company that develops, manufactures and markets diagnostic test kits and related medical products. Its portfolio covers gastrointestinal conditions, infectious diseases, food intolerances and point-of-care testing solutions, serving clinical labs, healthcare providers and retail healthcare segments across North America, Europe and Asia.
Anbio Biotechnology is a specialized in vitro diagnostic (IVD) biotechnology enterprise that develops, manufactures and markets a wide range of rapid testing solutions. Its product portfolio covers infectious disease detection, cardiovascular marker tests, food safety screening kits and supporting diagnostic tools, serving clinical labs, healthcare facilities and supervision bodies across global markets.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2M | — | ||
| Q3 25 | $1.4M | — | ||
| Q2 25 | $749.0K | — | ||
| Q1 25 | $1.1M | — | ||
| Q4 24 | $1.6M | — | ||
| Q3 24 | $1.8M | — | ||
| Q2 24 | $1.1M | — | ||
| Q1 24 | $1.0M | — |
| Q4 25 | $-1.3M | — | ||
| Q3 25 | $2.0K | — | ||
| Q2 25 | $-1.5M | — | ||
| Q1 25 | $-1.2M | — | ||
| Q4 24 | $-950.0K | — | ||
| Q3 24 | $-1.3M | — | ||
| Q2 24 | $-1.4M | — | ||
| Q1 24 | $-1.9M | — |
| Q4 25 | 4.2% | — | ||
| Q3 25 | 30.7% | — | ||
| Q2 25 | -33.0% | — | ||
| Q1 25 | 1.7% | — | ||
| Q4 24 | 26.7% | — | ||
| Q3 24 | 16.0% | — | ||
| Q2 24 | 2.1% | — | ||
| Q1 24 | -14.7% | — |
| Q4 25 | -113.5% | — | ||
| Q3 25 | -81.0% | — | ||
| Q2 25 | -209.1% | — | ||
| Q1 25 | -108.1% | — | ||
| Q4 24 | -60.7% | — | ||
| Q3 24 | -75.7% | — | ||
| Q2 24 | -136.6% | — | ||
| Q1 24 | -196.7% | — |
| Q4 25 | -109.1% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | -206.1% | — | ||
| Q1 25 | -103.9% | — | ||
| Q4 24 | -58.1% | — | ||
| Q3 24 | -72.8% | — | ||
| Q2 24 | -127.1% | — | ||
| Q1 24 | -188.6% | — |
| Q4 25 | $-0.45 | — | ||
| Q3 25 | $0.00 | — | ||
| Q2 25 | $-0.99 | — | ||
| Q1 25 | $-0.48 | — | ||
| Q4 24 | $-0.06 | — | ||
| Q3 24 | $-0.63 | — | ||
| Q2 24 | $-2.57 | — | ||
| Q1 24 | $-0.11 | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
